Keyphrases
Prednisone
100%
Chemotherapy
100%
Granulocyte Colony-stimulating Factor (G-CSF)
100%
Rituximab
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Doxorubicin
100%
Network Studies
100%
Wisconsin
100%
Oncological Networks
100%
Cyclophosphamide
100%
Previously Untreated
100%
Progression-free Survival
25%
Overall Survival
25%
Complete Response
25%
Recombinant
12%
Newly Diagnosed
12%
Elderly Patients
12%
High-risk Disease
12%
One Percent
12%
Effector Cells
12%
Survival Outcomes
12%
International Prognostic Index
12%
Antibody-dependent Cellular Cytotoxicity
12%
Event-free Survival
12%
Prognostic Score
12%
Chemotherapy Toxicity
12%
Dose Intensity
12%
Chemotherapy Cycles
12%
Survival Events
12%
Rituximab-containing Chemotherapy
12%
De Novo Diffuse Large B-cell Lymphoma
12%
CD20 Expression
12%
Medicine and Dentistry
Oncology
100%
Diffuse Large B-Cell Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Cyclophosphamide
100%
Prednisone
100%
Vincristine
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Progression Free Survival
28%
Overall Survival
28%
Elderly Patient
14%
Event Free Survival
14%
CD20
14%
Effector Cell
14%
International Prognostic Index
14%
Antibody Dependent Cellular Cytotoxicity
14%
Recombinant Granulocyte Macrophage Colony Stimulating Factor
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
Chemotherapy
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Diffuse Large B Cell Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Cyclophosphamide
100%
Vincristine
100%
Progression Free Survival
28%
Overall Survival
28%
Event Free Survival
14%
Recombinant Granulocyte Macrophage Colony Stimulating Factor
14%
Cytotoxicity
14%
Diseases
14%